Premium
Comorbidity as predictor poor prognosis for patients with advanced head and neck cancer treated with major surgery
Author(s) -
Omura Go,
Ando Mizuo,
Saito Yuki,
Kobayashi Kenya,
Yamasoba Tatsuya,
Asakage Takahiro
Publication year - 2016
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.23897
Subject(s) - comorbidity , medicine , head and neck cancer , head and neck , cancer , cancer surgery , intensive care medicine , oncology , surgery
Background The impact of comorbidities on patients with advanced head and neck cancer treated with major surgery has not been reported before. Methods We retrospectively reviewed clinical charts between 2004 and 2011 at our institution and identified 185 patients with clinical stage III to IV head and neck cancer treated with major surgery. Comorbidities were scored using the Adult Comorbidity Evaluation‐27 (ACE‐27) index manual. Results Patients with ACE‐27 ≥2 had significantly worse overall survival (OS) and disease‐specific survival (DSS) than those with ACE‐27 ≤1 ( p < .0001 and p = .0047, respectively). Multivariate analyses revealed that ACE‐27 ≥2 and extracapsular spread (ECS) were independently significant adverse prognostic factors for OS and DSS. In addition, patients with ACE‐27 ≥2 had a higher incidence of distant metastases ( p = .0057). Conclusion The current study suggests that comorbidities may predict poor prognosis and development of distant metastases for patients with advanced head and neck cancer treated with major surgery. © 2015 Wiley Periodicals, Inc. Head Neck 38: 364–369, 2016